by James Radke, PhD | Aug 24, 2022
Jennifer McNary, Head of Patient Advocacy and Engagement at Fulcrum Therapeutics, and mother to two boys with Duchenne muscular dystrophy, discusses the importance of clinically meaningful primary outcomes in clinical trials. Fulcrum Therapeutics is enrolling...
by James Radke, PhD | Aug 15, 2022
Guillaume Canaud, MD, PhD, of the Paris Descartes University, explains why it is important to regularly measure objective outcomes in persons with PiK3CA-related overgrowth syndrome (PROS). PROS is a group of rare congenital disorders that lead to the...
by James Radke, PhD | Aug 3, 2022
Annette von Drygalski, MD, PharmD, Associate Clinical Professor of Medicine in the Division of Hematology/Oncology, and Director of the Hemophilia and Thrombosis Treatment Center, Department of Medicine, at the University of California, San Diego, discusses...
by James Radke, PhD | Jul 29, 2022
Paula Busse, MD, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, provides a summary of the latest information about hereditary angioedema (HAE) that was presented at the American Academy of Allergy, Asthma, & immunology 2022...
by James Radke, PhD | Jul 15, 2022
Evan S. Dellon, MD, MPH, Gastroenterologist, and Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina Chapel Hill, explains two things that physicians should know about eosinophilic esophagitis (EoE). EoE is a chronic,...
